Akagi Yu, Awano Nobuyasu, Inomata Minoru, Kuse Naoyuki, Tone Mari, Yoshimura Hanako, Jo Tatsunori, Takada Kohei, Kumasaka Toshio, Izumo Takehiro
Department of Respiratory Medicine, Japanese Red Cross Medical Center, Japan.
Department of Pathology, Japanese Red Cross Medical Center, Japan.
Intern Med. 2020 Apr 15;59(8):1075-1080. doi: 10.2169/internalmedicine.3889-19. Epub 2020 Feb 1.
Immune checkpoint inhibitors have changed the landscape of classic cancer treatment. However, their use is associated with the emergence of new adverse events. An elderly man with rheumatoid arthritis was started on pembrolizumab for newly diagnosed advanced lung cancer. He subsequently developed hemophagocytic lymphohistiocytosis (HLH), which is potentially fatal but has not been properly established as an immune checkpoint inhibition-induced event. We herein report the case of a patient with pembrolizumab-induced HLH.
免疫检查点抑制剂已经改变了经典癌症治疗的格局。然而，它们的使用与新的不良事件的出现有关。一名患有类风湿性关节炎的老年男性开始使用派姆单抗治疗新诊断的晚期肺癌。他随后发展为噬血细胞性淋巴组织细胞增生症（HLH），这可能是致命的，但尚未被确认为免疫检查点抑制引起的事件。我们在此报告一例派姆单抗诱导的HLH患者的病例。
